Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Geometric means (percentage of the coefficient of variation) of anti-tetanus toxoid antibody titers taken 14 and 28 days after tetanus toxoid vaccination

From: Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

Group n Baseline titers (U/ml) Anti-tetanus antibody titers at 14 days post-vaccination (U/ml) Anti-tetanus antibody titers at 28 days post-vaccination (U/ml)
Group A (vaccines alone on day 1) 20 1.6 (106) 11.4 (88) 9.3 (104)
Group B (vaccines 2 weeks before abatacept) 20 1.9 (76) 10.2 (71) 8.7 (68)a
Group C (vaccines 2 weeks after abatacept) 19b 2.3 (76) 5.9 (112) 5.6 (98)
Group D (vaccines 8 weeks after abatacept) 19c 2.3 (54) 9.0 (79) 7.8 (85)
  1. an = 19 as one subject discontinued due to an adverse event (this discontinued patient only had samples collected at baseline and day 14). bSubject discontinued prior to vaccine administration on day 14 due to toxicology. cSubject discontinued prior to vaccine administration on day 56 due to toxicology.